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Hypothesis: Menière’s disease microRNA (miRNA) profiles are unique and are reflected
in the perilymph and serum of patients.
Background: Development of effective biomarkers for Menière’s disease are needed.
miRNAs are small RNA sequences that downregulate mRNA translation and play a
significant role in a variety of disease states, ultimately making them a promising
biomarker. miRNAs can be readily isolated from human inner ear perilymph and serum,
and may exhibit disease-specific profiles.
Methods: Perilymph sampling was performed in 10 patients undergoing surgery; 5
patients with Meniere’s disease and 5 patients with otosclerosis serving as controls.
miRNAs were isolated from the serum of 5 patients with bilateral Menière’s disease
and compared to 5 healthy age-matched controls. For evaluation of miRNAs an Agilent
miRNA gene chip was used. Analysis of miRNA expression was carried out using Qlucore
and Ingenuitey Pathway Analysis software. Promising miRNAs biomarkers were validated
using qPCR.
Results: In the perilymph of patients with Menière’s disease, we identified 16 differentially
expressed miRNAs that are predicted to regulate over 220 different cochlear genes.
Six miRNAs are postulated to regulate aquaporin expression and twelve miRNAs are
postulated to regulate a variety of inflammatory and autoimmune pathways. When
comparing perilymph with serum samples, miRNA-1299 and−1270 were differentially
expressed in both the perilymph and serum of Ménière’s patients compared to controls.
Further analysis using qPCR confirmed miRNA-1299 is downregulated over 3-fold in
Meniere’s disease serum samples compared to controls.
Conclusions: Patients with Ménière’s disease exhibit distinct miRNA expression profiles
within both the perilymph and serum. The altered perilymph miRNAs identified can
be linked to postulated Ménière’s disease pathways and may serve as biomarkers.
miRNA-1299 was validated to be downregulated in both the serum and perilymph of
Menière’s patients.
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INTRODUCTION
Menière’s disease is a chronic debilitating disorder of the inner
ear, characterized by fluctuating episodes of vertigo, hearing loss,
tinnitus, and aural pressure (1). Menière’s disease affects 250–500
per 100,000 people and has repeatedly been shown to negatively
impact patient’s quality of life comparable to many other
more common chronic medical diseases (2, 3). Since Prosper
Menière first recognized this debilitating disease over 150 years
ago, we have made significant strides to further understand
the pathophysiology of Menière’s disease. Most notably, 75
years ago post-mortem temporal bone analysis demonstrated
endolymphatic hydrops as a pathologic correlate to Menière’s
disease (4). However, despite our best efforts, there remains a
significant knowledge gap in the pathophysiology, diagnosis, and
management of Menière’s disease. While post-mortem studies
have offered invaluable information and insights (5), we still have
a limited understanding of what is occurring on a molecular
level in patients with active Menière’s disease, particularly in the
early stages of the disease and other inner ear disorders with
fluctuating symptoms.
The inner ear is a complex, delicate, fluid-filled structure that
lies deep within the temporal bone of the skull. Unfortunately, a
biopsy equivalent of the inner ear is not feasible, and diagnosis
of the different diseases often rely on various forms of hearing
performance testing. However, hearing performance testing such
as the audiogram, do not always accurately reflect the true
underlying pathology (6). As a result of these shortcomings, there
is significant interest in obtaining a “liquid biopsy” equivalent of
the inner ear. Many investigators are analyzing the components
of inner ear fluid to gain insights into what may be occurring on
a molecular level in active inner ear disease states (7–12).
Diagnosis of Menière’s disease is categorized as “probable”
or “definite” based on a composition of fluctuating and variable
clinical criteria established by the Bárány Society and adopted
by the American Academy of Otolaryngology Head and Neck
Surgery (13, 14). New diagnostic methodology has aided
to refine the diagnosis of Menière’s disease using objective
electrophysiologic testing and/or imaging, however testing is
not always reliable and thus not routinely recommended (15).
Unfortunately, there is no single diagnostic test for Menière’s
disease that serves as the gold standard. This is a result of
our limited knowledge of the underlying pathology resulting
in Menière’s disease. Multiple pathophysiology mechanisms
have been postulated including genetic (16), vascular (17, 18),
immunologic (18–20), aberrant aquaporin expression (21), or a
combination of causes.
Evaluation of micro RNA (miRNA) perilymph profiles in
inner ear disease may help define the hearing loss on a
molecular level (11). Inner ear diseases from otosclerosis to
profound sensorineural hearing loss (SNHL) exhibit distinct
miRNA profiles (22, 23). miRNAs are 19–23 base pair single
stranded RNA sequences that regulate post translation gene
expression through messenger RNA (mRNA) silencing (24).
miRNA molecules are conserved throughout multiple species,
have been identified in tissue and fluids throughout the body,
and are known to play a significant role in various pathologies
including cancer and other neurodegenerative diseases (25, 26).
miRNAs have also been shown to play a key role in inner ear
development and show distinct expression patterns in patients
with hearing loss compared to healthy controls, making them an
intriguing biomarker (27–30). In previous work, we preliminary
established Meniere’s disease could be diagnosed based on
perilymph miRNA profile alone, further validating miRNAs as a
potential biomarker either through the perilymph or serum of
patients (31).
In the current study we analyzed the miRNA profiles
of patients with Menière’s disease, collected at the time of
labyrinthectomy, and compare their profiles to patients with
otosclerosis. With the goal of identifying potential Menière’s
specific biomarkers, we compared the differentially expressed
miRNAs within the perilymph and compared it to serummiRNA
profiles in patients with active bilateral Menière’s disease and
healthy age matched controls.
METHODS
Human perilymph sampling was approved by the University
of Kansas Human Studies Committee and Institutional Review
Board (Study00142630). All experiments performed were in
accordance with relevant guidelines and regulations. Patients
were recruited for perilymph sampling if they were undergoing
a surgical procedure where the inner ear was already being
opened. miRNA perilymph profiling was performed using two
disease classes, Menière’s disease and otosclerosis. For Menière’s
disease, perilymph was collected at the time of labyrinthectomy
for patients with intractable symptoms and who failed hearing
conservative management. Perilymph sampling in patients with a
healthy and normal ear is not currently feasible, therefore we used
otosclerosis patients as a control since they have minimal SNHL.
Patients with SNHL secondary to otosclerosis were not included.
All patients received standard of care and underwent surgical
treatment with either stapedotomy or labyrinthectomy. When
the patient’s inner ear was opened for their indicated procedure,
a small sterile glass capillary tube was used to collect ∼2–5 µL
volume of perilymph (11).
In the second part of this project, we sought to evaluate if
the perilymph profile of Meniere’s disease is also reflected in the
serum of patients. An overlap would indicate that miRNAs may
serve as a promising biomarker for Menière’s disease. In order
to evaluate serum miRNA profiles, human serum was collected,
and miRNAs were isolated from five patients with active bilateral
Menière’s disease. Serum miRNA profiles from Menière’s disease
were compared to five healthy age matched controls.
Patient Selection and Audiometry
All patients underwent pure tone audiometry prior to their
respective procedures. Air and bone conduction thresholds
were determined, and a CT scan of the temporal bone was
performed for all patients with diagnosis of otosclerosis. Only
patients with conductive hearing loss (CHL) and radiologically
confirmed otosclerosis were included in the CHL control group
(n = 5). For the Meniere’s disease cohort, patient’s required the
diagnosis of “definite Meniere’s” based on the Bárány Society
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and adopted by the American Academy of Otolaryngology Head
and Neck Surgery (13, 14). This included documented low to
mid frequency SNHL, episodic vertigo that lasts 20min to 12 h,
and aural symptoms (fullness and/or tinnitus). Patients were
diagnosed with bilateral Meniere’s disease if they fit “definite
Meniere’s,” where symptoms lateralized to both ears (tinnitus,
aural fullness, pressure) and documented low frequency SNHL
in both ears at some point in their Meniere’s history. A total
of five patients (n= 5) underwent labyrinthectomy for poorly
controlled Menière’s disease who had failed hearing conservative
therapy including dietary control, diuretics, betahistine, and/or
endolymphatic sac decompression. Patients were not considered
for intratympanic gentamycin injections.
Perilymph Sampling During Stapedectomy
The skin of the external auditory canal was injected with 0.5ml
of 1% lidocaine + 1:100,000 epinephrine. Using a round knife,
a cut was made in the skin of the external canal and small
tympanomeatal flap was carefully elevated medially revealing
the middle ear structures. Using the OmniguideTM CO2 laser
with a power setting of four watts, 0.1 s single bursts, the
stapes superstructures were removed. Using the laser, a rosette
fenestration was made in the stapes footplate. Upon making
the fenestration, perilymph could be seen coming out from the
vestibule. We then removed excess perilymph with a sterile glass
capillary tube. After successful collection of perilymph fluid,
the stapes footplate fenestration was enlarged to accommodate




Through a post auricular incision, a standardmastoidectomy was
performed and the horizontal semicircular canal was identified.
The horizontal semicircular canal was carefully blue lined with
a diamond drill and opened on one posterior end to allow
free flow of perilymph out of the inner ear. The perilymph
sample was obtained using a sterile glass capillary tube. A
standard labyrinthectomy was performed following collection of
adequate sample.
Human Serum Sampling
Five patients with bilateral active Menière’s disease based on 2015
Barany Society diagnostic criteria and five age matched healthy
controls were enrolled. Six ml of whole blood was collected from
each participant and transferred to tubes containing EDTA. The
samples were then spun down at 2,000×g for 15min. The serum
layer was then pipetted off and frozen at −20◦C. Once all 10
samples were collected, microRNA was isolated from the serum
using Qiagen miRNeasy Serum/Plasma Kit (Cat No./ID 217184).
MicroRNA Analysis
Perilymph collection has been previously described (11, 23).
Total RNA was extracted with Trizol reagent (Thermofisher,
cat #15596018) and purified by centrifuging with a phase lock
heavy gel (Tiagen, cat # WMS-2302830). MicroRNA from serum
samples was extracted as described above. Samples from both
perilymph and serum were analyzed with an Agilent RNA6000
Pico kit using an Agilent Bioanalyzer 2100 yielding on average
0.5–2 ng of total RNA per sample. Samples were processed and
analyzed with an Affymetrix miRNA 4.0 array to determine
the presence of micro RNAs as per manufacturer instructions.
The Affymetrix miRNA 4.0 array interrogates all miRNA
sequences listed in miRBase Release 20; interrogating 30,434
mature miRNAs from 203 organisms of which 2,578 are from
humans. The arrays were background corrected, normalized,
and gene-level summarized using the Robust Multichip Average
(RMA) algorithm. In order to ascertain which miRNAs were
significantly expressed in each array, for each miRNA probe
in the array, a detection p-value was computed based on
a Wilcoxon Rank-Sum test of the miRNA probe set signals
compared to the distribution of a GC matched background
signal comprising of anti-genomic probes in the same array.
The detection p-values were adjusted for multiple hypothesis
testing (FDR) using the Benjamini and Hochberg method. These
analyses were performed using Affymetrix Expression Console
Software. miRNAs with a normalized log2 signal intensity ≥ 7
and an adjusted detection p-value (FDR) ≤ 0.05 were considered
significantly expressed in the assay.
To further understand miRNA interaction within the human
cochlea as it relates directly to Menière’s disease, we approached
analysis in a two-step process. First, we compared the perilymph
miRNA profiles between patients with Menière’s disease and
otosclerosis (control) to differentiate which miRNAs are unique
to Menière’s disease using Qlucore software (Qlucore Inc.,
Lund Sweden). The miRNA expression data were then analyzed
using Ingenuity Pathway Analysis (IPA) software (Qiagen
Bioinformatics, Redwood City, CA). In order to further
understand miRNA interactions within the human inner ear, we
used IPA software to predict potential interactions with genes
expressed in a normal hearing human cochlea (GEO Series
accession number GSE128505) (10, 29). Secondly, in order to
identify miRNAs that are clinically relevant, we screened the
identified miRNA-mRNA interactions for genes that have been
identified to play a pathologic role in Meniere’s disease in either
animal models or population studies (30–33). Key miRNAs
identified were then compared the miRNA expression levels
in the serum of patients with Meniere’s disease and controls.
MicroRNA data from serum samples was analyzed by microarray
as described above with a focus on miRNAs that had been
identified as differentially expressed in serum.
Serum miRNA qPCR Validation Analysis
After running microRNA arrays from the serum samples,
residual RNA from the samples was validated by Q-RT-PCR.
Two serum samples were excluded from further processing
due to low RNA concentration, one control and one from
the Meniere’s cohort. A second sample from the Meniere’s
cohort was excluded from analysis due to genomic DNA
contamination, leaving 4 samples in the control group and
3 in the Meniere’s group. cDNA was synthesized using the
miScript II reverse transcription kit (Qiagen, cat#218161). qPCR
was then performed on the BioRad CFX using the miScript
SYBR Green miRNA PCR system (Qiagen, cat#218073). All
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TABLE 1 | Audiometric data for both patient cohorts.
Meniere’s disease Otosclerosis
Number of patients 5 5
Age (years) (Mean ± Std) 66.6 ± 18.1 52.2 ± 10.6
PTA (dB) (Mean ± Std)
Air 69.2 ± 18.8 58 ± 6.7
Bone 60.8 ± 23.2 30.4 ± 8.6
reactions were performed in triplicate and the Ct value was
determined using the threshold calculated by the BioRad
software. Mir-191-5p was used for normalization based on
its stable expression across treatment and control samples.
The universal primer from the miScript SYBR Green miRNA
PCR kit (Qiagen, cat#218073) was used as the reverse primer
for each reaction. MiScript primer assays for hsa-miR-191-5p
(5′ CAACGGAATCCCAAAAGCAGCTG 3′) and hsa-miR-1270
(5′ CTGGAGATATGGAAGAGCTGTG 3′) were used as forward
primers for qPCR (Qiagen, cat#218300). The hsa-miR-1299
forward primer sequence was 5′ CTGGAATTCTGTGTGAGGG
3′. Fold change was calculated using the 2−11CT method (32).
RESULTS
Perilymph miRNA Profile in Meniere’s
Disease vs. Otosclerosis (CHL/Controls)
In order to identify which miRNAs are unique to Meniere’s
disease, we compared the perilymph miRNA expression profiles
between Meniere’s disease (n = 5) and otosclerosis (n = 5)
(Table 1). One significant challenge is that perilymph sampling in
patients with normal hearing is not currently feasible. Therefore,
patients with otosclerosis serve as our control, given this
pathology is largely exclusive to the stapes footplate. Tomaximize
this patient population as controls, we excluded patients with
SNHL secondary to advanced otosclerosis. Using gene expression
analysis, we identified 16 unique miRNAs that were significantly
downregulated in patients with Menière’s disease (Table 2).
The 16 miRNAs altered in Menière’s disease were screened
for targets in a human cochlear cDNA library using IPA
software. Analysis was only limited to miRNA-mRNA prediction
interactions that have either been experimentally proven or “high
probability” based on paired nucleotide sequencing between
miRNA and mRNA. The 16 miRNAs unique to Meniere’s disease
were predicted to interact with over 220 genes within the
cochlea. To focus our search, we only analyzed proposed gene
candidates that have been proven to play a pathologic role in
Meniere’s disease through either animalmodels or human genetic
population studies. Aberrant aquaporin regulation have been
consistently linked to Menière’s disease in both experimental
models and population studies (33, 34). Altered regulation of
both pathways have been linked to Menière’s disease as well
(18, 35–37). Six of the 16 miRNAs are predicted to regulate
aquaporin gene expression (Table 3). Twelve of the 16 miRNAs



















TABLE 3 | MiRNAs unique to Meniere’s disease perilymph that are postulated to




hsa-miR-4746-5p AQP2 + AQP4
hsa-miR-1299 AQP2
hsa-miR-1255a AQP3 + AQP4
hsa-miR-1270 AQP4
TABLE 4 | MiRNAs differentially expressed in Meniere’s disease perilymph and
their inflammatory pathway targets.
Micro RNA Inflammatory pathway targets
hsa-miR-542-3p KRTAP6-3, LINC01169, R3HDM2
hsa-miR-6853-5p POLR2J2/ POLR2J3, NME4
hsa-miR-424-3p OTOR, HIGD1A, RNF13
hsa-miR-1243 RNF13, LYRM2, RPS16, RAP1B








are predicted to regulate either inflammatory or autoimmune
regulatory pathways (Table 4).
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Evaluating Human Serum miRNA Profiles
for Potential Biomarkers
An ideal candidate Menière’s disease biomarker would be
identifiable within both the perilymph and serum of patients,
thereby allowing us to evaluate the function of the inner ear based
on a serum sample. We collected and isolated miRNAs in the
serum of patients with bilateral active Menière’s disease (n = 5)
and age matched controls (n = 5). Using miRNA array analysis,
we identified 79 alternately expressed miRNAs in the serum of
patients with Menière’s disease compared to controls. miRNA-
1299 and−1270 were uniquely and differentially expressed in the
perilymph and serum of patients with Menière’s disease, making
both promising biomarkers. Both miRNA-1299 and-1270 were
linked to inflammatory and autoimmune pathways. miRNA-1299
can be linked to aquaporin expression.
To further evaluate if either miRNA-1299 or−1270 could be
utilized as a Menière’s disease biomarker, qPCR was utilized to
validate if both were unique and exclusive to Meniere’s disease
serum. Using the 2−11CT method, miRNA-1299 downregulated
3.13-fold in the serum of patients with Menière’s disease
compared to controls. However, miRNA-1270 had similar
expression levels in the serum of both patient cohorts (fold
change= 0.923).
DISCUSSION
There is a need for a surrogate marker for Meniere’s disease,
to not only serve as a diagnostic marker but also help further
elucidate what may be occurring on a molecular level. This study
is one of the first studies to describe the miRNA profiles in
patients with Menière’s disease. By evaluating and comparing
miRNA perilymph and serum profiles in patients with Menière’s
disease to controls, miRNA-1299 was identified exclusively in
patients with Menière’s and may serve as a promising disease
specific biomarker.
miRNAs have shown significant potential as a reliable
biomarker for otherwise difficult to diagnose diseases (26, 38, 39).
miRNAs are small non-coding RNAs that downregulate gene
expression through various negative feedback loops (39). Using
IPA software, we are able to identify potential miRNA—mRNA
interactions in a human cochlear cDNA library to gain further
insight into various aberrant pathways in Menière’s disease.
However, this type of analysis is limited. We can only interrogate
and infer mRNA regulation, and we do not directly identify genes
involved with Menière’s disease (24). Despite this limitation,
we know miRNAs play a key mechanistic role in various inner
ear pathologies such as sudden hearing loss and inner ear
development (26, 27, 29, 30). Additionally, miRNAs have been
identified within all main cellular compartments, exosomes,
and cell free components throughout the body and have been
successfully used as biomarkers for other neurodegenerative
diseases like Alzheimer’s and Parkinson’s (25, 36, 37). Finally,
in previous work, we found miRNAs exhibit inner ear disease
specific profiles and that various inner ear pathologies can
be diagnosed based on miRNA profiles alone (11, 22, 23).
Taken together, miRNAs offer an intriguing biomarker for
Menière’s disease.
We identified 16 unique miRNAs that were significantly
downregulated in the perilymph of patients with Menière’s
disease. While these 16 miRNAs were proposed to regulate over
220 different genes within the cochlea, we narrowed our focus
to gene pathways that have been shown to play a pathologic role
in Menière’s disease. Aquaporins are a group of intramembrane
proteins that serve as water channels in various cellular processes
and have been shown to potentially play a key pathogenic role in
Menière’s disease (21, 40). In guinea pig models, endolymphatic
hydrops can be induced through administration of vasopressin,
resulting in upregulation of aquaporins (33). In humans, AQP2
and AQP3 have been shown to be aberrantly expressed in
genetic population studies (34). It was promising that not only
unique miRNAs were identified in Menière’s patient cohorts,
but that their genetic interactions are linked to pathways
that have been identified in Menière’s disease. IPA software
predicted that miRNA-1255 and−1243 target to AQP3 mRNA,
and miRNA-4746 and−1299 are target AQP2 mRNA. Compared
to previous miRNA perilymph studies on sudden and progressive
sensorineural hearing loss, there was no overlap observed in the
16 significant miRNAs identified in this study (29, 30).
Twelve of the 16 miRNAs unique to Menière’s disease are
directly predicted to regulate inflammation and/or autoimmune
pathways. Recent research supports the link between
inflammation, cellular degeneration, and the pathogenesis of
Menière’s disease (16). By analyzing the perilymph proteome in
patients with Menière’s disease, Lin et al. discovered 38 proteins
that were differentially expressed in patients with Menière’s
disease and strongly linked to tissue injury and inflammation
(10). Several pathologic mechanisms have been proposed
for Menière’s diseases involving inflammatory pathways
including viral-induced inflammation (10), otitis media
induced inflammatory products and toxins (41), circulating
immune complexes leading to increase cellular permeability
(37, 42), genetic predisposition to altered NF-KB mediated
inflammatory response (43), distinct and altered cytokine
profiles (44), and autoimmunity (37, 45). Together, these studies
suggest a strong correlation between Meniere’s disease and an
aberrant inflammation cascade. Genes that were predicted to
be targeted by two or more of the twelve miRNAs associated
with inflammation included TNFRSF11B, RAP1B, NMNAT2,
RPS16, R3HDM2, STEAP2, and SCP2. Altered TNF expression
has been proposed to play a significant role in Meniere’s disease
and TNF-α inhibitors are being preliminarily investigated as a
therapeutic intervention (45, 46). From our identified miRNAs,
miRNA-1299 was identified as the most promising biomarker
for Menière’s disease since it is differentially regulated in both
perilymph and serum of Menière’s patients, and is predicted to
target R3HDM2, SCP2, and ATP5POmRNA.
While perilymph and serum miRNAs have been uniquely
linked to Menière’s disease and miRNA-1299 shows potential
as viable disease biomarker, there are several limitations to
this study. First, by analyzing miRNAs within the perilymph,
we are studying a small subset of miRNAs that are limited
to the extracellular exosomes or cell free miRNA and not
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evaluating tissue directly (47). Secondly, although promising
miRNAs were identified, the small sample size severely limits
statistical analysis and ability to draw stronger conclusions.
Future prospective studies will need to increase the sample
size and evaluate these miRNA biomarkers as compared to
other inner ear pathologies that can present simultaneously
with Menière’s disease, such as sensorineural hearing loss. For
example, future studies will need to compare Meniere’s miRNA
profiles to patients with known isolated genetic causes of SNHL,
such as patients with the DFNA9 mutation. Third, we anticipate
that larger cohorts may also reveal that different subtypes of
Meniere’s disease as suggested by epidemiological studies (48).
Furthermore, if these miRNA biomarkers remain promising in
larger studies, future research endeavors will need to validate
their mechanism of action. As further samples are collected
for disease specific biomarkers, it will be critical to not only
collect perilymph and serum samples from the same patients, but
also compare miRNA disease profiles in patients with unilateral
and bilateral active Menière’s disease. Finally, statistically
significant miRNAs identified in this study are different from
our machine learning studies (31). We hypothesize differences
are likely attributed to machine learning methodology, which
is focused on miRNA complex pattern matching and not solely
differences in single miRNA expression levels. Approaches in
this study helped find statistically significant miRNAs based on
expression alone, whereas machine learning may find a subset
of miRNAs and how their expression pattern, both upregulation
and downregulation, may be interconnected and unique to
various inner ear pathologies. Future work will need to further
understand the validity of both methodological approaches and
how they can help identify single miRNAs as compared to
assay like expression patterns of miRNA biomarkers for inner
ear pathologies.
CONCLUSION
The pathophysiology and disease mechanisms driving Menière’s
disease remain unclear. While a direct tissue biopsy of the inner
ear is not feasible, perilymph sampling has shown significant
promise as a “liquid biopsy.” In this study, Menière’s disease
not only demonstrated a unique and distinct miRNA profile
compared to controls, but unique miRNAs can be directly
linked to proven or well-accepted aberrant disease mechanisms
underlying Menière’s disease. miRNA-1299 is differentially
expressed in the perilymph and serum of patients with Menière’s
disease, predicted to regulate both aquaporin and inflammatory
disease mechanisms linked to Menière’s disease, and may
ultimately serve as a promising biomarker. While definitive
conclusions are limited by a small sample size, miRNA profiling
in patients with Menière’s disease is a feasible methodology
to further elucidate what may be occurring a molecular level
and identify future biomarkers to diagnose, prognose, and
guide treatment.
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